| Literature DB >> 35743390 |
Yuko Ogata1, Naoya Kobayashi1, Masanori Yamauchi1.
Abstract
Transcatheter aortic valve implantation (TAVI) is an effective treatment for severe aortic stenosis (AS); however, postoperative delirium (POD) can worsen patient outcomes. This study aimed to examine the risk factors for POD after TAVI, including possible intervening factors. We included 87 patients (mean age: 83) who underwent TAVI between May 2014 and September 2018. POD was defined by the presence or absence of delirium on ICU admission, assessed using the Confusion Assessment Method for the ICU. Factors that showed significant differences in the univariate analysis were analyzed using a multiple logistic regression analysis. In total, 31 patients (36%) had POD after ICU admission, and 56 (64%) did not. The preoperative frailty score and aortic valve opening area (AVA) were significant risk factors for POD. The multivariate analysis also showed that both factors were independent risk factors for POD (area under the receiver operating characteristic curve: 0.805). There were no significant differences in the number of ICU days. However, postoperative hospitalization was significantly longer in the POD group (19 (17-31) days vs. 16 (13-22) days; p = 0.002). POD was associated with a narrow AVA and frailty; this suggests that frailty prevention interventions according to the AVA may be important.Entities:
Keywords: aortic stenosis; postoperative delirium; transcatheter aortic valve implantation
Year: 2022 PMID: 35743390 PMCID: PMC9225478 DOI: 10.3390/jcm11123317
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Patient characteristics.
| POD 1 | Non-POD | |||||
|---|---|---|---|---|---|---|
|
| 31 | 56 | ||||
| Age, median (years) | 84 | (80, 88) | 83 | (81, 86) | 0.759 | |
| Female | 25 | (80.6 %) | 40 | (71.4 %) | 0.344 | |
| Body mass index (kg/m²) | 22.7 | (20.3, 24.7) | 22 | (20.5, 23.6) | 0.47 | |
| Severity scores | ||||||
| Frailty index | 4 | (3, 5) | 2 | (1, 3) | <0.001 | ** |
| MMSE 2 | 25 | (22, 27) | 27 | (24, 29) | 0.02 | * |
| STS 3 score | 6.7 | (5.3, 10.9) | 6 | (4.5, 8.4) | 0.125 | |
| EURO 4 score | 6.1 | (4.5, 10.0) | 3.8 | (2.9, 5.5) | 0.006 | ** |
| NYHA 5 | 0.002 | ** | ||||
| I | 0 | (0 %) | 0 | (0 %) | ||
| II | 13 | (14.9 %) | 41 | (73 %) | ||
| III | 14 | (16.1 %) | 15 | (27 %) | ||
| IV | 4 | (4.6 %) | 0 | (0 %) | ||
| Comorbidities | ||||||
| Hypertension | 22 | (25.3 %) | 43 | (76.8 %) | 0.55 | |
| Atrial fibrillation | 2 | (2.3 %) | 2 | (3.6 %) | 0.539 | |
| Pacemaker implantation | 1 | (1.1 %) | 3 | (5.4 %) | 0.649 | |
| Diabetes mellitus | 9 | (10.3 %) | 12 | (21.4 %) | 0.427 | |
| Stroke | 1 | (1.1 %) | 5 | (8.9 %) | 0.315 | |
| Myocardial infarction | 2 | (2.3 %) | 2 | (3.6 %) | 0.539 | |
| PCI 9 | 7 | (8 %) | 10 | (17.9 %) | 0.595 | |
| Angina | 0 | (0 %) | 4 | (7.1 %) | 0.128 | |
| Dementia | 2 | (2.3 %) | 0 | (0 %) | 0.055 | |
| COPD 10 | 3 | (3.4 %) | 3 | (5.4 %) | 0.446 | |
| Carotid artery disease | 1 | (1.1 %) | 3 | (5.4 %) | 0.649 | |
| Rheumatoid arthritis | 2 | (2.3 %) | 2 | (3.6 %) | 0.539 | |
| Current smoker | 6 | (6.9 %) | 16 | (28.6 %) | 0.344 | |
| Habitual drinking | 2 | (2.3 %) | 11 | (20 %) | 0.098 | |
| Use of sleeping pills | 9 | (10.3 %) | 18 | (32.1 %) | 0.764 | |
| Physiological variables | ||||||
| Albumin (g/L) | 3.6 | (3.2, 3.8) | 3.7 | (3.4, 4) | 0.07 | |
| pre-BNP 7 (pg/dL) | 203.2 | (93.4, 603.2) | 178 | (78, 425.8) | 0.257 | |
| GFR 8 (mL/mL/1.73mm²) | 42 | (35, 56) | 53 | (40, 77) | 0.021 | * |
| FEV 6 1.0 < 70% | 9 | (29 %) | 8 | (14.3 %) | 0.097 | |
| Outcomes | ||||||
| ICU-free days 30days (days) | 28 | (27, 28) | 28 | (27.3, 28.6) | 0.258 | |
| Postoperative hospital stays (days) | 19 | (17, 31) | 16 | (13, 22) | 0.002 | ** |
| Mortality | 0 | (0 %) | 0 | (0 %) | 1 | |
Patient characteristics in the POD and non-POD groups are shown separately. Values represent the number of patients (rates) or median (interquartile range). The Wilcoxon test and Fisher’s exact test were used to compare data between POD and non-POD patients. * p < 0.05, ** p < 0.01. 1 POD, postoperative delirium; 2 MMSE, Mini-Mental State Examination; 3 STS, Society of Thoracic Surgeons; 4 EURO, European System for Cardiac operative Risk Evaluation; 5 NYHA, New York Heart Association; 6 FEV, forced expiratory volume in one second; 7 BNP, brain natriuretic peptide; 8 GFR, glomerular filtration rate; 9 PCI, peri-cutaneous coronary intervention; 10 COPD, chronic obstructive pulmonary disease.
Preoperative transthoracic echocardiography.
| POD 4 | Non-POD | |||||
|---|---|---|---|---|---|---|
|
| 31 | 56 | ||||
| Aortic valve | ||||||
| Peak jet velocity (m/s) | 5.0 | (4.6, 5.3) | 4.6 | (4.2, 5.4) | 0.115 | |
| Maximal gradient (mmHg) | 100 | (83, 113) | 83 | (71, 119) | 0.133 | |
| Mean gradient (mmHg) | 56 | (46, 67) | 50 | (39, 70) | 0.226 | |
| AVA 1 (cm2) | 0.56 | (0.45, 0.62) | 0.69 | (0.58, 0.84) | <0.001 | ** |
| AVAI 2 (cm2/m2) | 0.42 | (0.35, 0.50) | 0.51 | (0.42, 0.60) | 0.020 | * |
| Left ventricular function | ||||||
| Ejection fraction (%) | 64 | (57, 71) | 65 | (57, 73) | 0.529 | |
| End-diastolic volume (mL/m2) | 47 | (44, 51) | 46 | (41, 50) | 0.401 | |
| End-systolic volume (mL/m2) | 30 | (27, 33) | 29 | (25, 34) | 0.356 | |
| Left ventricular expandability | ||||||
| DcT 3 (msec) | 201 | (168, 303) | 235 | (181, 310) | 0.643 | |
| E/A | 0.7 | (0.5, 0.9) | 0.6 | (0.5, 0.8) | 0.598 | |
| E/e’ | 19.3 | (15.8, 27.4) | 19.7 | (15.6, 24.0) | 0.793 | |
The risk factors for POD are shown separately. Values are expressed as medians (interquartile ranges). The Wilcoxon test was used to compare the data between POD and non-POD patients. * p < 0.05, ** p < 0.01. 1 AVA, continuity equation valve area; 2 AVAI, continuity equation valve area index; 3 DcT, deceleration time of early diastolic filling velocity wave; 4 POD, postoperative delirium.
Intraoperative factors of POD.
| POD 1 | Non-POD | |||||
|---|---|---|---|---|---|---|
|
| 31 | 56 | ||||
| Anesthesia | ||||||
| Sedative agents | 0.003 | ** | ||||
| Gas | 17 | (54.8 %) | 13 | (23.2 %) | ||
| Total intravenous anesthesia | 14 | (45.2 %) | 43 | (76.8 %) | ||
| Anesthesia time, median (IQR) 2 | 286 | (260, 340) | 262 | (244, 283) | 0.002 | ** |
| Operation time, median (IQR) | 153 | (130, 213) | 141 | (122, 160) | 0.019 | * |
| Time from start of surgery to dilation (IQR) | 81 | (65, 107) | 75 | (61, 94) | 0.087 | |
| Operation | ||||||
| Approach | 0.756 | |||||
| Trans-femoral | 28 | (90.3 %) | 51 | (91.1 %) | ||
| Trans-apical | 1 | (3.2 %) | 3 | (5.4 %) | ||
| Subclavian | 2 | (6.5 %) | 2 | (3.6 %) | ||
| Device | 0.293 | |||||
| CoreValveTM/EvolutTM R | 15 | (48.4 %) | 23 | (41.1 %) | ||
| Edwards SAPIEN | 16 | (51.6 %) | 33 | (58.9 %) | ||
| Prosthesis size | 26 | (83.9 %) | 26 | (46.4 %) | 0.348 | |
The risk factors for POD are shown separately. Values represent the number of patients (rates) or median (interquartile range). The Wilcoxon test and Fisher’s exact test were used to compare data between POD and non-POD patients. * p < 0.05, ** p < 0.01. 1 POD: postoperative delirium, 2 IQR: Inter-quartile range.
Risk factors of postoperative delirium.
| Odds Ratio | 95% CI | |||
|---|---|---|---|---|
| Aortic valve area (per −0.1) (cm2) | 1.95 | (1.17–3.27) | 0.004 | ** |
| Frailty index (per +1) | 2.49 | (1.37–4.54) | <0.001 | ** |
Factors that showed significant differences in the univariate analysis were analyzed using multiple logistic regression analysis. R2: 0.321; area under the curve of receiver operating characteristic (AUROC): 0.840; Akaike’s Information Criterion (AIC): 61.9. ** p < 0.01. CI: confidence interval.
Figure 1Receiver operating characteristic curve for prediction of POD.